NSE F&O Ban: Delta Corp, GNFC, India Cements, ZEEL, other stocks under ban on August 16, Wednesday The National Stock Exchange (NSE) banned the trading in futures and options (F&O) of nine stocks/securities on Wednesday, August 16, 2023. India Cements, GNFC, Chambal Fertilisers, Delta Corp, Granules India, ZEEL, Indiabulls Housing Finance, Manappuram Finance, and Balrampur Chini Mills are the stocks/securities placed on the National Stock Exchange’s futures and options (F&O) ban for trade on Wednesday. According to the NSE, the stocks mentioned above are prohibited in the F&O sector because they have exceeded 95% of the market-wide position limit (MWPL). During the F&O ban period, no new positions are permitted for F&O contracts in that stock. “The Nifty index displayed volatility throughout the trading session, before ending the day with minimal change. On the daily chart, it’s evident that the index received support at the 50EMA, leading to a notable intraday rebound. However, the RSI on the daily chart demonstrated a bearish crossover, with its value dropping below 50. This could be indicative of a weakening trend. If the index falls below the 19,250 mark, it might incite a corrective movement toward the 19,100 – 19,150 range in the near future. Conversely, resistance can be identified at the 19,550 level on the higher side,” said Rupak De, Senior Technical analyst at LKP Securities. On Tuesday, the equity benchmarks were closed on account of Independence Day. Prior to that, on Monday, domestic indices ended in green. The NSE Nifty 50 gained 6.25 points or 0.03% to 19,434.55 and BSE Sensex rose 79.27 points or 0.12% to 65,401.92. Among the broader indices, the Nifty 100 fell 0.15%, Nifty Next 50 sank 1.25% and the Nifty 200 plunged 0.15%, while Nifty Midcap 50 gained 0.05%. In sectoral indices, Bank Nifty tumbled 108.15 points or 0.24% to 44,090.95, Nifty Auto fell 0.33%, Nifty Metal sank 2.14%, Nifty Pharma fell 0.33%, Nifty PSU Bank plunged 0.71%, Nifty Private Bank fell 0.05% and the Nifty Realty tanked 0.66% while Nifty IT climbed 0.68%, Nifty FMCG gained 0.49% and Nifty Media surged 0.87%. The top gainers on Nifty 50 were Divi’s Labs, Infosys, LTIMindtree, Hindustan Unilever and RIL while the top losers were Adani Enterprises, JSW Steel, Hindalco Industries, State Bank of India and Adani Ports & Special Economic Zone.
The regulator had undertaken a series of surveillance actions to ensure that the volatility in the Adani group companies’ share prices was contained. This will be a part of the brief to the finance minister on Wednesday, the sources said.
The Japanese pharma major is also filing a plea before the Delhi HC seeking appointment of forensic auditors to analyse transactions involving IHH, Fortis Healthcare and RHT, Singapore, as directed by the HC on October 18.
The development is likely to create legal hurdles and delay the proposed open offer as IHH had recently told FE that it could only go ahead if Sebi agreed with its legal interpretation that the SC’s September 22 order has lifted all such restraints.
IHH managing director and CEO Kelvin Loh told FE on November 9 that the company would like to go ahead with the open offer “as soon as possible” as there has already been a delay of four years. Ravi Rajagopal, chairman of Fortis Healthcare, had added that their legal counsel has advised that the company can go ahead with the open offer as the SC order has disposed of various appeals, including the suo motu contempt. “We have represented to the Sebi and the matter is with them,” Rajagopal had said.
However, legal observers told FE that the matter is not that straightforward and simple as the Delhi HC has to take the final call on the matter of open offer as well as whether a forensic audit has to be done in the share sale which was executed in 2018.
Also Read: IHH to float open offer for Fortis if Sebi concurs with our legal view: MD & CEO
Loh and Rajagopal had said the possibility that the matter may take a different turn when it comes up in Delhi HC cannot be ruled out.
IHH had in July 2018 acquired a 31% stake in Fortis Healthcare for Rs 4,000 crore through the bidding route. It had also earmarked Rs 3,000 crore to make an open offer for an additional 26% to the public shareholders as required under the law.
Daiichi has written to Sebi that the SC in its September 22 order had asked the HC to consider ordering a forensic audit into the dilution of FHL shareholding, repeated violation of undertakings and assurance by former FHL promoters — Malvinder and Shivinder Singh — and the transaction between FHL, IHH and the clandestine transfer of Rs 4,666 crore to RHT Singapore.
Daiichi is “severely prejudiced” with IHH’s clandestine attempt to subvert the status quo order directed by the SC on December 14, 2018, and September 22 with respect to the conduct of forensic audit and the pending proceedings before the HC by purportedly consulting regulatory authorities, including Sebi, on the proposed FHL-IHH transaction. It has reiterated that the FHL-IHH transaction was currently sub-judice before the HC where FHL is also a party, its solicitors, P&A Law Offices, have said in the letter.
“We further state that any such attempt by FHL and/or IHH to proceed with the FHH-IHH transaction would be in direct contravention of the HC and SC orders,” the letter sent by the law firm has stated. Daiichi Sankyo is pursuing the enforcement of Rs 3,500-crore arbitration award against the Singh brothers pronounced by a Singapore tribunal for concealing information when they sold Ranbaxy Laboratories to it for $4.6 billion in 2008. The apex court had in 2018 put on hold the sale of Fortis Healthcare to IHH on a contempt plea filed by the Japanese drugmaker against the Singh brothers.